Compare Indonesia Energy Corporation Limited (INDO) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Novartis AG — how do they compare? Indonesia Energy Corporation Limited trades at $2.74 (market cap $42.16M), while Novartis AG trades at $143.75 (market cap $272.15B). The key difference: Novartis AG is far larger — about 6455.2× Indonesia Energy Corporation Limited's market cap, and Novartis AG pays a 3.3% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and Novartis AG for 82 Days on average.
| INDO | NVS | |
|---|---|---|
Market Cap | $42.16M | $272.15B |
Volume | 69,323 | 1,900,903 |
Sector | Energy | Health |
52-Week High | $6.74 | $168.62 |
52-Week Low | $2.49 | $121.80 |
Typical Hold Time | 24 Days | 82 Days |
Enterprise Value | $37.10M | $313.48B |
Dividend Yield | — | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Indonesia Energy Corporation (INDO) trades at $2.81, up 1.44% with a bearish technical outlook despite 100% analyst buy ratings. The oil and gas explorer shows severe financial stress with negative margins (-152.7% net income margin) and consistent quarterly losses, though recent K-29 well discoveries offer operational catalysts. Cash flow remains dependent on financing activities as operations burn $5.43M annually.
High-risk speculative opportunity exists given the disconnect between negative fundamentals and optimistic analyst sentiment. Success hinges on new well production scaling revenue to achieve profitability. Key risks include execution delays, sustained cash burn, and oil price volatility that could threaten liquidity without additional financing.
Novartis (NVS) trades at $143.11, down 0.12% with a bearish technical signal. The stock shows strong fundamentals with 24.67% net margin and $14B net income, though recent earnings were mixed with a Q1 miss. Analyst consensus is cautious with 68% hold ratings and a $146 target. Recent $7.8B licensing deal with China's Abogen highlights strategic moves amid pipeline setbacks.
Outlook remains balanced: valuation metrics appear reasonable (P/E 21.6) and profitability is robust, but clinical trial failures and investor scrutiny over M&A strategy pose risks. The stock trades near consensus target with institutional sentiment leaning neutral amid ongoing pipeline execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
